Empagliflozin-Induced Acute Pancreatitis and Euglycemic Diabetic Ketoacidosis in Type 2 Diabetes Mellitus
American Journal of Chemistry and Pharmacy · 2022
DOI: 10.54536/ajcp.v1i2.747 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Chemistry and Pharmacy, 2022. Verfasst von Sadawey Yasser und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Acute pancreatitis and euglycemic DKA, EDKA, are uncommon but potentially fatal complications in diabetic patients on sodium-glucose cotransporter 2 inhibitors (SGLT2). This case report presents the exceptional occurrence of a 49-year-old; male patient diagnosed with empagliflozin-induced EDKA coupled with T2DM as a precursor to acute pancreatitis. Euglycemic DKA may be produced after administering just one dose of SGLT2. On discharge, empagliflozin was managed to stop. Since the initial administration of SGLT2, this diagnosis should be considered a potential consequence. Appropriate medical treatment is made possible by diagnosing and treating this life-threatening condition promptly.
Zitieren
APA
Yasser, S., & Hesham, M. (2022). Empagliflozin-Induced Acute Pancreatitis and Euglycemic Diabetic Ketoacidosis in Type 2 Diabetes Mellitus. American Journal of Chemistry and Pharmacy. https://doi.org/10.54536/ajcp.v1i2.747
Vancouver
Yasser S, Hesham M. Empagliflozin-Induced Acute Pancreatitis and Euglycemic Diabetic Ketoacidosis in Type 2 Diabetes Mellitus. American Journal of Chemistry and Pharmacy. 2022. doi:10.54536/ajcp.v1i2.747
BibTeX
@article{Yasser2022,
author = {Yasser, Sadawey and Hesham, Metwally},
title = {Empagliflozin-Induced Acute Pancreatitis and Euglycemic Diabetic Ketoacidosis in Type 2 Diabetes Mellitus},
journal = {American Journal of Chemistry and Pharmacy},
year = {2022},
doi = {10.54536/ajcp.v1i2.747}
}
EUVIMED